| Autor: |
Zuidmeer-Jongejan L; Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands. l.zuidmeer@amc.uva.nl., Fernandez-Rivas M, Poulsen LK, Neubauer A, Asturias J, Blom L, Boye J, Bindslev-Jensen C, Clausen M, Ferrara R, Garosi P, Huber H, Jensen BM, Koppelman S, Kowalski ML, Lewandowska-Polak A, Linhart B, Maillere B, Mari A, Martinez A, Mills CE, Nicoletti C, Opstelten DJ, Papadopoulos NG, Portoles A, Rigby N, Scala E, Schnoor HJ, Sigurdardottir ST, Stavroulakis G, Stolz F, Swoboda I, Valenta R, van den Hout R, Versteeg SA, Witten M, van Ree R |
| Jazyk: |
angličtina |
| Zdroj: |
Clinical and translational allergy [Clin Transl Allergy] 2012 Mar 09; Vol. 2 (1), pp. 5. Date of Electronic Publication: 2012 Mar 09. |
| DOI: |
10.1186/2045-7022-2-5 |
| Abstrakt: |
The FAST project (Food Allergy Specific Immunotherapy) aims at the development of safe and effective treatment of food allergies, targeting prevalent, persistent and severe allergy to fish and peach. Classical allergen-specific immunotherapy (SIT), using subcutaneous injections with aqueous food extracts may be effective but has proven to be accompanied by too many anaphylactic side-effects. FAST aims to develop a safe alternative by replacing food extracts with hypoallergenic recombinant major allergens as the active ingredients of SIT. Both severe fish and peach allergy are caused by a single major allergen, parvalbumin (Cyp c 1) and lipid transfer protein (Pru p 3), respectively. Two approaches are being evaluated for achieving hypoallergenicity, i.e. site-directed mutagenesis and chemical modification. The most promising hypoallergens will be produced under GMP conditions. After pre-clinical testing (toxicology testing and efficacy in mouse models), SCIT with alum-absorbed hypoallergens will be evaluated in phase I/IIa and IIb randomized double-blind placebo-controlled (DBPC) clinical trials, with the DBPC food challenge as primary read-out. To understand the underlying immune mechanisms in depth serological and cellular immune analyses will be performed, allowing identification of novel biomarkers for monitoring treatment efficacy. FAST aims at improving the quality of life of food allergic patients by providing a safe and effective treatment that will significantly lower their threshold for fish or peach intake, thereby decreasing their anxiety and dependence on rescue medication. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink